Datafin

Data-driven stock analysis platform for global investors.

Sitemap
HomeScreenerValuationSector Analysis
Resources
LibraryDatafin GuideMetric MethodologyValuation MethodologiesFAQPricingWho Is Datafin?Communication
Legal
Privacy PolicyTerms of UseCookie PolicyKVKK NoticeRefund Policy
Data Sources

Financial data sourced from official regulatory filings and verified market data providers. Metrics calculated using GAAP/IFRS standards.

Disclaimer

The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

Investment decisions involve risk. Verify data independently and consult a licensed advisor when needed.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved.

Last updated: April 2026

TERA PEER ANALYSIS

Tera Yatirim Menkul Degerler A.S. — metric-by-metric comparison with peers and the industry median

TERATera Yatirim Menkul Degerler A.S.

🇹🇷 Turkey · IS · Financial Services · Capital Markets

Value itDuel
PriceFinancialsPeers

Overall Profile & Returns

· Capital Markets

Position Within Industry

0 = weak quartile, 100 = strong quartile
ValuationProfitabilityGrowthFinancial HealthDividend
TERAIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year
Split-adjusted
TERA+89.8%PWP-15.4%CLSK+10.3%MKTX-45.3%LAZ-10.6%HUB-8.4%
Year-to-Date (YTD)
TERA-13.5%PWP+0.3%CLSK+33.5%MKTX-35.1%LAZ-9.1%HUB-13.0%
1-Year
Split-adjusted
TERA+89.8%ISMEN+0.9%GEDIK-1.3%OYYAT+24.6%
Year-to-Date (YTD)
TERA-13.5%ISMEN-2.7%GEDIK+38.7%OYYAT+2.5%

Key Metric Comparison

P/E

Lower is better
TERA2.14PWP88.99CLSK—MKTX13.32LAZ16.91HUB64.80Median 18.71

ROE

Higher is better
TERA138.1%PWP—CLSK-34.8%MKTX24.4%LAZ37.4%HUB19.7%Median 19.1%

Net Margin

Higher is better
TERA10.8%PWP2.9%CLSK-67.7%MKTX35.3%LAZ8.5%HUB23.2%Median 9.1%

Revenue Growth

Higher is better

P/E

Lower is better
TERA2.14ISMEN7.49GEDIK8.19OYYAT6.03Median 18.71

ROE

Higher is better
TERA138.1%ISMEN23.0%GEDIK40.8%OYYAT19.4%Median 19.1%

Net Margin

Higher is better
TERA10.8%ISMEN0.4%GEDIK0.3%OYYAT6.7%Median 9.1%

Revenue Growth

Higher is better

All Metrics

Valuation
MetricTERAPWPCLSKMKTXLAZHUBInd. Median
P/E2.14●88.99—13.3216.9164.8018.71
P/B1.73-11.29●3.673.465.2412.582.86
EV/EBITDA0.61●38.2821.828.5911.4339.5310.61
P/S———————
Financial Health
MetricTERAPWPCLSKMKTXLAZHUBInd. Median
Current Ratio1.551.078.2624.26●5.615.891.61
Debt/Equity26.2%-117.7%●181.6%24.5%245.3%17.0%67.0%
NetDebt/EBITDA-1.37●2.164.17-0.321.910.21-0.02
Profitability
MetricTERAPWPCLSKMKTXLAZHUBInd. Median
Net Margin10.8%2.9%-67.7%35.3%●8.5%23.2%9.1%
ROE138.1%●—-34.8%24.4%37.4%19.7%19.1%
ROA45.1%●3.4%-18.0%14.8%6.5%15.8%4.4%
EBITDA Margin———————
Growth + Dividend
MetricTERAPWPCLSKMKTXLAZHUBInd. Median
Rev. Growth———————
NI Growth421.8%●——42.8%-8.9%80.4%36.9%
Div. Yield0.0%1.7%1.0%2.7%4.8%●0.9%1.2%
Payout0.0%139.8%-7.2%36.9%68.0%43.0%23.1%
Valuation
MetricTERAISMENGEDIKOYYATInd. Median
P/E2.14●7.498.196.0318.71
P/B1.731.462.880.95●2.86
EV/EBITDA0.610.495.130.07●10.61
P/S—————
Financial Health
MetricTERAISMENGEDIKOYYATInd. Median
Current Ratio1.551.231.102.55●1.61
Debt/Equity26.2%●61.0%260.2%41.6%67.0%
NetDebt/EBITDA-1.37-1.86●0.08-1.51-0.02
Profitability
MetricTERAISMENGEDIKOYYATInd. Median
Net Margin10.8%●0.4%0.3%6.7%9.1%
ROE138.1%●23.0%40.8%19.4%19.1%
ROA45.1%●5.5%7.1%9.3%4.4%
EBITDA Margin—————
Growth + Dividend
MetricTERAISMENGEDIKOYYATInd. Median
Rev. Growth—————
NI Growth421.8%●-11.5%348.0%386.2%36.9%
Div. Yield0.0%12.4%●8.7%0.0%1.2%
Payout0.0%93.2%71.2%0.0%23.1%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on TERA

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 3, 26. This content is for informational purposes only and is not investment advice.